NSE: AUROPHARMA | BSE: 524804

Turnaround Potential

Download real time

1206.20 -5.20 (-0.43%)

319.6K NSE+BSE Volume

NSE 26 Dec, 2025 3:31 PM (IST)

70,056.3

Market Cap

High in industry

Beta 1Year

High Volatility

Aurobindo Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AUROPHARMA, BSE:524804 Aurobindo Pharma Ltd.

Search Inside the pdf :

Aurobindo Pharma Ltd.

03 Dec 2025

1206.20

-0.43%

Broad-based growth momentum building up

Buy: Aurobindo Pharma Ltd.

Target

Motilal Oswal

With considerable investment (INR35b) done till date by Aurobindo Pharma (ARBP) in the Pen-G/6-APA project and support from the government under the PLI scheme, ARBP is scaling up the production to enhance self-sufficiency of India in bulk drugs/intermediates to be used for Beta-Lactum antibiotics.

Aurobindo Pharma Ltd. is trading above its 200 day SMA of 1141.0

Aurobindo Pharma Ltd.

10 Nov 2025

1206.20

-0.43%

Aurobindo Pharma Ltd.

Buy: Aurobindo Pharma Ltd.

Target

ICICI Direct

Q2FY26- Muted numbers on expected lines Revenues grew ~6% YoY to 8286 crore due to softness in the US (44% of the revenues) which grew 3% to 3638 crore. Europe (30% of the revenues) grew 18% to 2480 crore and ARV (~4% of the revenues) grew 68% to 325 crore. Growth Markets (~10% of the revenues) grew ~9% YoY to 882 crore (including India formulations). APIs de-grew at 17% YoY to 961 crores. EBITDA grew 7% YoY to 1678 crore while EBITDA margins increased 16 bps to 20.3%. EBITDA de-growth was mainly driven by increase in employee expenses....

Aurobindo Pharma Ltd. is trading below its 30 day SMA of 1208.5

Aurobindo Pharma Ltd.

10 Nov 2025

1206.20

-0.43%

Outlook supported by recovery in Injectables, ramp-up of Pen-G and biosimilars

Accumulate: Aurobindo Pharma Ltd.

Target

Deven Choksey

Aurobindo Pharma delivered a steady quarter, with revenue growth driven mainly by formulations, particularly Europe and a stable US base supported by new product launches.

Aurobindo Pharma Ltd. is trading above its 200 day SMA of 1141.0

Aurobindo Pharma Ltd.

07 Nov 2025

1206.20

-0.43%

Aurobindo Pharma (ARBP IN) Q2FY26 Result Update In...

Buy: Aurobindo Pharma Ltd.

Prabhudas Lilladhar

Promoters pledged 0.42% of shares in last quarter. Total pledge stands at 17.50% of promoter holdings

Aurobindo Pharma Ltd.

07 Nov 2025

1206.20

-0.43%

Steady quarter, growth projects on track

Buy: Aurobindo Pharma Ltd.

Target

ICICI Securities Limited

Aurobindo’s Q2FY26 performance was steady, helped by its Europe (+17.8%) and ARV (68.4%) verticals. US sales, at USD 417mn, beat our expectation; though, gRevlimid sales slipped sequentially.

Aurobindo Pharma Ltd. is trading above its 200 day SMA of 1141.0

Aurobindo Pharma Ltd.

07 Nov 2025

1206.20

-0.43%

Result Update:Aurobindo Pharma

Buy: Aurobindo Pharma Ltd.

Target

Axis Direct

We maintain our BUY recommendation on the stock with a TP of Rs 1,345/share.

Aurobindo Pharma Ltd. is trading below its 30 day SMA of 1208.5

Aurobindo Pharma Ltd.

06 Nov 2025

1206.20

-0.43%

Margins intact despite lower g-Revlimid sales

Buy: Aurobindo Pharma Ltd.

Target

Motilal Oswal

Aurobindo Pharma (ARBP) reported an in-line performance in 2QFY26. Interestingly, the quarter saw lower contribution from g-Revlimid compared to earlier quarters.

Aurobindo Pharma Ltd. has an average target of 1349.22 from 9 brokers.

Aurobindo Pharma Ltd.

06 Aug 2025

1206.20

-0.43%

Result Update:Aurobindo Pharma

Buy: Aurobindo Pharma Ltd.

Target

Axis Direct

We maintain our BUY recommendation on the stock with a TP of Rs 1,400/share.

Aurobindo Pharma Ltd. is trading above its 200 day SMA of 1141.0

Aurobindo Pharma Ltd.

06 Aug 2025

1206.20

-0.43%

Aurobindo Pharma (ARBP IN) Q1FY26 Result Update Weak...

Buy: Aurobindo Pharma Ltd.

Target

Prabhudas Lilladhar

Aurobindo Pharma's (ARBP) Q1FY26 EBITDA of Rs16.1bn (down 1% YoY) was 5% below our estimate led by lower US sales. Resultant our FY26 and FY27E EPS stands reduced by 5-10%. The company has maintained its 20-21% OPM guidance for FY26E despite gRevlimid sales loss. We expect margins and revenues to improve from H2FY26/FY27 with ramp up in PenG facility, Vizag pant commercialization and launches in US. We believe ARBP has multiple growth drivers in place with investments in vaccines, injectables, biosimilars...

Aurobindo Pharma Ltd. has an average target of 1349.22 from 9 brokers.

Aurobindo Pharma Ltd.

05 Aug 2025

1206.20

-0.43%

Growth in EU/ARV; margin contraction drags PAT

Buy: Aurobindo Pharma Ltd.

Recommendation Target

Motilal Oswal

Aurobindo Pharma (ARBP) delivered lower-than-expected performance for 1QFY26. While revenue was in line with estimates, EBITDA/PAT missed our estimates by 7%/8% for the quarter.

Number of FII/FPI investors decreased from 728 to 700 in Sep 2025 qtr

Is Aurobindo Pharma Ltd. worth buying?

1260 Votes:

Buy 80.24%

Sell 13.73%

Hold 6.03%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf